Matinas BioPharma to Collaborate With NIAID to Test Remdesivir
07 December 2020 - 11:22PM
Dow Jones News
By Chris Wack
Matinas BioPharma Holdings Inc. said Monday it plans to
collaborate with the National Institute of Allergy and Infectious
Diseases, part of the National Institutes of Health, to test oral
formulations of remdesivir in preclinical models.
Remdesivir is owned by Gilead Sciences Inc., and the lipid
nanocrystal platform is owned by Matinas. Any product generated as
a part of efforts by Matinas and NIAID would require a license from
Gilead for the use of remdesivir and a license from Matinas for the
use of the LNC formulation.
One or more formulations of remdesivir will be developed using
Matinas' Lipid Nanocrystal platform delivery technology, which
enables the development of a wide range of difficult-to-deliver
molecules.
Matinas said it plans to use NIAID's suite of preclinical
services to carry out antiviral testing with selected formulations.
Gilead will provide remdesivir and work with Matinas to evaluate
the data generated from the planned series of preclinical
studies.
Matinas shares were up 13% to $1.23 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 07, 2020 07:07 ET (12:07 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From Apr 2024 to May 2024
Gilead Sciences (NASDAQ:GILD)
Historical Stock Chart
From May 2023 to May 2024